Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial
Launched by NANCHANG UNIVERSITY · Jun 28, 2010
Trial Information
Current as of August 26, 2025
Unknown status
Keywords
ClinConnect Summary
lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative
- Exclusion Criteria:
- • Primary MN patients, HBV-DNA positive
About Nanchang University
Nanchang University is a prestigious research institution located in Nanchang, China, known for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its robust academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. By fostering collaboration among researchers, clinicians, and industry partners, Nanchang University aims to facilitate the development of new therapies and treatment modalities, ensuring rigorous adherence to ethical standards and regulatory compliance throughout the trial process. The university's dedication to evidence-based medicine and patient-centered research underscores its role as a leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Gaosi XU, MD & PhD
Study Director
second affiliated hospital to nanchang university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials